<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:00:53Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8202713" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8202713</identifier>
        <datestamp>2021-09-16</datestamp>
        <setSpec>gatesmanu</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">N Engl J Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">N Engl J Med</journal-id>
              <journal-title-group>
                <journal-title>The New England Journal of Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0028-4793</issn>
              <issn pub-type="epub">1533-4406</issn>
              <publisher>
                <publisher-name>Massachusetts Medical Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8202713</article-id>
              <article-id pub-id-type="pmcid">PMC8202713</article-id>
              <article-id pub-id-type="pmc-uid">8202713</article-id>
              <article-id pub-id-type="pmid">34525285</article-id>
              <article-id pub-id-type="pmid">34525285</article-id>
              <article-id pub-id-type="doi">10.1056/NEJMoa2035916</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian
Children</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patel</surname>
                    <given-names>Priyanka D.</given-names>
                  </name>
                  <degrees>M.B.B.S.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref rid="FN1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patel</surname>
                    <given-names>Pratiksha</given-names>
                  </name>
                  <degrees>M.B.B.S.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref rid="FN1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liang</surname>
                    <given-names>Yuanyuan</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref rid="FN2" ref-type="author-notes">§</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Meiring</surname>
                    <given-names>James E.</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref rid="FN2" ref-type="author-notes">§</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Misiri</surname>
                    <given-names>Theresa</given-names>
                  </name>
                  <degrees>M.P.H.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mwakiseghile</surname>
                    <given-names>Felistas</given-names>
                  </name>
                  <degrees>M.Sc.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tracy</surname>
                    <given-names>J. Kathleen</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Masesa</surname>
                    <given-names>Clemens</given-names>
                  </name>
                  <degrees>M.Sc.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Msuku</surname>
                    <given-names>Harrison</given-names>
                  </name>
                  <degrees>B.Sc.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Banda</surname>
                    <given-names>David</given-names>
                  </name>
                  <degrees>B.Sc.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mbewe</surname>
                    <given-names>Maurice</given-names>
                  </name>
                  <degrees>B.Sc.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Henrion</surname>
                    <given-names>Marc</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Adetunji</surname>
                    <given-names>Fiyinfolu</given-names>
                  </name>
                  <degrees>M.P.H.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Simiyu</surname>
                    <given-names>Kenneth</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rotrosen</surname>
                    <given-names>Elizabeth</given-names>
                  </name>
                  <degrees>A.B.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Birkhold</surname>
                    <given-names>Megan</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nampota</surname>
                    <given-names>Nginache</given-names>
                  </name>
                  <degrees>M.B.B.S.</degrees>
                  <xref ref-type="aff" rid="A5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nyirenda</surname>
                    <given-names>Osward M.</given-names>
                  </name>
                  <degrees>B.Sc.</degrees>
                  <xref ref-type="aff" rid="A5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kotloff</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gmeiner</surname>
                    <given-names>Markus</given-names>
                  </name>
                  <degrees>M.Sc.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dube</surname>
                    <given-names>Queen</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="A6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kawalazira</surname>
                    <given-names>Gift</given-names>
                  </name>
                  <degrees>M.B.B.S.</degrees>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Laurens</surname>
                    <given-names>Matthew B.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Heyderman</surname>
                    <given-names>Robert S.</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="A8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gordon</surname>
                    <given-names>Melita A.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="aff" rid="A9">9</xref>
                  <xref ref-type="aff" rid="A10">10</xref>
                  <xref rid="FN3" ref-type="author-notes">#</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Neuzil</surname>
                    <given-names>Kathleen M.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref rid="FN3" ref-type="author-notes">#</xref>
                </contrib>
                <on-behalf-of>on behalf of the TyVAC Malawi team</on-behalf-of>
              </contrib-group>
              <aff id="A1"><label>1</label>Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi;</aff>
              <aff id="A2"><label>2</label>Center for Vaccine Development and Global Health, University of
Maryland School of Medicine, Baltimore, Maryland, USA;</aff>
              <aff id="A3"><label>3</label>Oxford Vaccine Group, Department of Paediatrics, Oxford
University, United Kingdom;</aff>
              <aff id="A4"><label>4</label>Liverpool School of Tropical Medicine, Liverpool, UK;</aff>
              <aff id="A5"><label>5</label>Blantyre Malaria Project, University of Malawi College of
Medicine, Blantyre, Malawi;</aff>
              <aff id="A6"><label>6</label>Department of Paediatrics, Queen Elizabeth Central Hospital,
Blantyre, Malawi.</aff>
              <aff id="A7"><label>7</label>District Health Office, Blantyre District Council, Blantyre,
Malawi;</aff>
              <aff id="A8"><label>8</label>Division of Infection and Immunity, University College
London;</aff>
              <aff id="A9"><label>9</label>Institute of Infection, Veterinary and Ecological Sciences,
University of Liverpool, United Kingdom;</aff>
              <aff id="A10"><label>10</label>College of Medicine, University of Malawi, Malawi.</aff>
              <author-notes>
                <fn fn-type="equal" id="FN1">
                  <label>*</label>
                  <p id="P1">P. D. P. and P. P. contributed equally to this manuscript.</p>
                </fn>
                <fn fn-type="equal" id="FN2">
                  <label>§</label>
                  <p id="P2">Y. L. and J. E. M. contributed equally to this manuscript.</p>
                </fn>
                <fn fn-type="equal" id="FN3">
                  <label>#</label>
                  <p id="P3">M. A. G. and K. M. N. contributed equally as senior researchers.</p>
                </fn>
                <fn>
                  <p>This is an Author Final Manuscript, which is the version after external peer
review and before publication in the Journal. The publisher’s version
of record, which includes all New England Journal of Medicine editing and
enhancements, is available at <ext-link ext-link-type="uri" xlink:href="http://www.nejm.org/doi/full/10.1056/NEJMoa2035916">10.1056/NEJMoa2035916</ext-link>.</p>
                </fn>
                <corresp id="CR1">Correspondence to: Professor Melita Gordon, NIHR Research Professor in
Global Health, P.O. Box 30096, Blantyre 3, Malawi
<email>magordon@liverpool.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>16</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>16</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <volume>385</volume>
              <issue>12</issue>
              <fpage>1104</fpage>
              <lpage>1115</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This Author Accepted Manuscript is licensed for use under the CC-BY
license.</license-p>
                </license>
              </permissions>
              <abstract id="ABS1">
                <sec id="S1">
                  <title>Background</title>
                  <p id="P222">Typhoid fever caused by multidrug-resistant H58 <italic>Salmonella</italic>
Typhi is an increasing public-health threat in sub-Saharan Africa. We present phase 3
efficacy data from an African trial of a Vi-polysaccharide typhoid conjugate vaccine
(Vi-TCV).</p>
                </sec>
                <sec id="S2">
                  <title>Methods</title>
                  <p id="P333">Children aged 9 months to 12 years in Blantyre, Malawi were randomized (1:1)
in a double-blind trial to receive Vi-TCV (single dose) or group-A meningococcal control
vaccine (MenA).The primary outcome was blood culture-confirmed typhoid fever. We present
the primary vaccine efficacy (VE) and safety outcomes after 18–24 months of
follow-up.</p>
                </sec>
                <sec id="S3">
                  <title>Results</title>
                  <p id="P4">This intention-to-treat (ITT) analysis included 28,130 children, comprising
14,069 children who received Vi-TCV and 14,061 children who received MenA. Blood
culture-confirmed typhoid fever occurred in 12 children in the Vi-TCV group (46.9 per
100,000 person-years) and 62 children in the MenA group (243 per 100,000 person-years).
Overall VE was 80.7% (95% confidence interval (CI): 64.2% to 89.6%) in an ITT analysis,
and 83.7% (95% CI: 68.1%−91.6%) in a per-protocol analysis. In total, 130 serious
adverse events occurred in the first 6 months after vaccination (52 in Vi-TCV group and
78 in MenA group), including 6 deaths (all in MenA group). No serious adverse event was
considered by the investigator as related to study vaccination.</p>
                </sec>
                <sec id="S4">
                  <title>Conclusions</title>
                  <p id="P5">Vi-TCV reduced blood culture-confirmed typhoid fever among Malawian children
aged 9 months to 12 years. (Funded by the Bill &amp; Melinda Gates Foundation; <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> number <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/ct2/show/NCT03299426">NCT03299426</ext-link>.)</p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <p id="P6">Typhoid fever, a systemic febrile illness caused by <italic>Salmonella
enterica</italic> serovar Typhi (<italic>S. typhi</italic>), is responsible for more than 9
million infections and over 110,000 deaths globally each year, with the highest disease burden
among school-age and pre-school children.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> An estimated 1.2 million typhoid cases and 18,703
deaths occur annually in sub-Saharan Africa, with 383-843 cases per 100,000 person-years
reported in some urban settings.<sup><xref rid="R3" ref-type="bibr">3</xref>–<xref rid="R5" ref-type="bibr">5</xref></sup></p>
            <p id="P7">The increased public health importance of typhoid fever across sub-Saharan Africa
over the past decade is due in part to emergence and spread of several multidrug resistant
(MDR; resistant to first-line agents chloramphenicol, ampicillin, and co-trimoxazole)
<italic>S. typhi</italic> lineages, particularly H58 (clade 4.3.1) and H56 (clade
3.1.1).<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> In Malawi and other countries in
East and Southern Africa, MDR H58 <italic>S. typhi</italic> emerged in 2010 following its
introduction from Asia,<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> becoming the predominant blood-stream infection among
adults and children, with 2% case fatality and 5% rate of small bowel perforation.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup> Emerging antimicrobial resistance to
fluoroquinolones has been documented in East Africa,<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup> Nigeria,<sup><xref rid="R6" ref-type="bibr">6</xref></sup> and Democratic Republic of Congo.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Extensively drug-resistant (XDR) typhoid, resistant to
fluoroquinolones and 3<sup>rd</sup> generation cephalosporins, is established in
Pakistan.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> The dual threat in Africa of
local emergence or introduction of untreatable XDR typhoid from Asia underscores the need for
typhoid fever prevention.<sup><xref rid="R15" ref-type="bibr">15</xref></sup></p>
            <p id="P8">In 2018, the World Health Organization (WHO) recommended typhoid conjugate vaccine
(TCV) for children 6 months through 15 years of age in countries with high incidence of
disease or antimicrobial resistance.<sup><xref rid="R16" ref-type="bibr">16</xref></sup>
Typbar TCV<sup>®</sup> (Bharat Biotech International) is a WHO-prequalified typhoid
conjugate vaccine. The Typhoid Vaccine Acceleration Consortium (TyVAC) was launched in 2017
with the aim to accelerate Vi-TCV introduction in low-income settings. TyVAC is conducting
large, randomized controlled efficacy trials of a Vi-TCV in diverse epidemiological settings
in Malawi, Nepal, and Bangladesh.<sup><xref rid="R17" ref-type="bibr">17</xref>–<xref rid="R19" ref-type="bibr">19</xref></sup> Here we present vaccine efficacy and safety
results for Vi-TCV from the African continent,<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> through 18–24 months of
follow-up, from a clinical trial of single dose Vi-TCV in Blantyre, Malawi.<sup><xref rid="R22" ref-type="bibr">22</xref></sup></p>
            <sec id="S5">
              <title>Methods</title>
              <sec id="S6">
                <title>Study design and participants</title>
                <p id="P9">This is a single center, phase 3, double-blind, individually randomized
active-controlled trial in two urban townships in Blantyre, Malawi. Detailed methods have
been published.<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> Briefly, a target of approximately 28,000 healthy
children were enrolled, aged 9 months through 12 years residing within the urban townships
of Ndirande and Zingwangwa, whose parents/guardians provided written consent, with no
previous history of typhoid vaccination, and no acute illness or history of allergy or
hypersensitivity. Written assent was required for children aged ≥8 years. HIV
status was solicited verbally and confirmed, if positive, using the participant’s
health-passport, where possible. Participants were recruited through government health
centers and primary schools. Safety data (Adverse Events (AEs) and Serious Adverse Events
(SAEs)) were prospectively recorded.</p>
                <p id="P10">The study was approved by the Malawi National Health Sciences Research Committee
(#17/07/1866); Malawi Pharmacy, Medicines, and Regulatory Authority (#3010201791);
University of Maryland, Baltimore Institutional Review Board (#HP-00076625); University of
Liverpool Research Ethics Committee (#2941).</p>
              </sec>
              <sec id="S7">
                <title>Randomization and masking</title>
                <p id="P11">Participants were randomized at a 1:1 ratio to receive a single dose of Vi-TCV
or control meningococcal group A conjugate vaccine (MenA), using block randomization with
block sizes from 6–12. The random allocation sequence was generated by the
blockrand package (version 1.3) in R (version 3.4.1) and concealed before randomization,
which occurred in real time immediately before vaccination. Parents, guardians,
participants, and study staff involved in screening, eligibility assessment, and follow-up
were fully blinded to vaccine-group assignment. Unblinded nurses prepared and administered
vaccine in a private area and had no further role in the study after vaccination.</p>
              </sec>
              <sec id="S8">
                <title>Procedures and vaccines</title>
                <p id="P12">Typbar TCV<sup>®</sup> consists of Vi polysaccharide conjugated to a
tetanus toxoid protein carrier (25 μg per 0.5 ml dose). MenA (MenAfriVac, Serum
Institute of India PVT Ltd) was given to children aged ≥1 year at a dose of 10
μg per 0.5 ml and 5 μg per 0.5 ml to children aged &lt;1 year. Vaccines
were administered intramuscularly in the left thigh (children aged &lt;1 year) or left
arm (children aged ≥ 1 year). Both Vi-TCV and MenA were co-administered with
routine measles-rubella vaccine (in the right thigh) in children aged 9–11 months
(Malawi Expanded Programme on Immunization). Bharat Biotech International Limited supplied
the Typbar TCV vaccine free of charge.</p>
              </sec>
              <sec id="S9">
                <title>Enhanced fever and safety surveillance</title>
                <p id="P13">All participants were monitored for 30 minutes after vaccination for immediate
AEs. Enhanced passive surveillance for fever and SAEs was conducted at four primary health
centers (Ndirande, Zingwangwa, Gateway, Nayo) in addition to Queen Elizabeth Central
Hospital, a government referral hospital, where parents/guardians were instructed to bring
unwell children at any time. Usual health service provision was also enhanced by telephone
and community messaging to participants. Children presenting with febrile illness
(subjective fever for ≥72 hours; axillary temperature ≥38°C; or
hospitalization with history of fever of any duration), had blood-culture collected (5 mL
&lt;5-year old; 10 mL &gt;=5 year old), and malaria Rapid Diagnostic Test (RDT).
Antimicrobial resistance of <italic>S. typhi</italic> isolates was tested by
disc-diffusion.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> Isolates showing
pefloxacin-resistance had confirmatory ciprofloxacin e-test (BioMerieux), minimum
inhibitory concentration &gt;0.06mg/L indicating resistance. Hospital admission and
antimicrobial treatment were at the facility clinician’s discretion. Participants
with blood-culture -confirmed <italic>S. typhi</italic> were followed up biweekly, until
asymptomatic, to monitor treatment response and outcome.</p>
              </sec>
              <sec id="S10">
                <title>Outcomes</title>
                <p id="P14">The primary outcome was blood-culture -confirmed typhoid fever occurring at any
time after vaccination. Vaccine efficacy (VE) was calculated as (1-IRR) × 100%,
where IRR is the incidence rate ratio (ratio of incidence in the Vi-TCV group compared
with the MenA group). Secondary outcomes were safety profiles of Vi-TCV and MenA measured
by 1) the number of AEs detected in the first 30 minutes after vaccination, 2) the number
of SAEs within 28 days after vaccination, and 3) the number of SAEs within 6 months after
vaccination. For the primary evaluation of VE, all children were under enhanced passive
surveillance for at least 18 months (21 February 2018 through 3 April 2020).</p>
              </sec>
              <sec id="S11">
                <title>Statistical analysis</title>
                <p id="P15">Details of sample size and power calculations have been reported.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> Briefly, assuming 75% VE, the minimum number
of cases needed to test the null hypothesis that the vaccine has no protective efficacy
(i.e., VE≤0), with 90% power, was 30. The primary analysis to test VE was based on
the intention-to-treat (ITT) principle, which included all randomized children who were
vaccinated and all first episodes of blood-culture -confirmed typhoid fever occurring
after vaccination. In the ITT analysis, the vaccine group was defined by the vaccine
randomly assigned, not by the vaccine received. Per-protocol VE analysis included children
who completed the study, without any protocol deviations, received the vaccine to which
they were assigned, and accrued first episodes of blood-culture -confirmed typhoid fever
at least 14 days after vaccination.</p>
                <p id="P16">Due to the interruption of surveillance activities caused by COVID-19 (3 April
2020 onwards), a protocol amendment in August 2020 changed the primary analysis endpoint
to 3 April 2020, encompassing 18–24 months follow-up per participant. The Data
Safety Monitoring Board (DSMB) approved the amendment, as the study had reached the
pre-specified number of typhoid cases and the prolonged disruption in surveillance would
affect evaluations of incidence, cases prevented, and number needed to vaccinate. Full
cohort blinded surveillance will continue until 30 Sept 2021 (minimum 36-month follow-up)
for secondary longer-term efficacy and subgroup analyses.</p>
                <p id="P17">The incidence rate was calculated as the number of first episodes of
blood-culture -confirmed typhoid fever divided by the total follow-up time. Individual
follow-up time was the smallest of the following: Time to first episode of typhoid fever;
time to withdrawal, loss to follow-up, death, or relocation out of study area; or time to
the end of the analysis period. The incidence rate ratio (IRR) was calculated as the ratio
of the incidence rate in the Vi-TCV to the MenA group, and VE was calculated as (1-IRR)
× 100%. Subgroup analysis was conducted to evaluate VE for sex, study site, and
&lt;5 years vs. ≥5 years of age at vaccination; Poisson regression with the
interaction term between each pre-planned subgroup of interest and the vaccine group was
used to compare VE across subgroups.</p>
                <p id="P18">Absolute risk reduction was calculated as the risk of blood-culture -confirmed
typhoid fever in the MenA group minus that in the Vi-TCV group. The number needed to
vaccinate was calculated as 1/absolute risk reduction, representing the number of children
who need to be vaccinated to prevent one additional blood-culture -confirmed case of
typhoid fever. The cumulative incidence of typhoid fever for each vaccine group was
presented using the Kaplan-Meier method; and VE was estimated at 12, 18, and 24 months
after vaccination using the life table method. All analyses were performed according to
the pre-specified statistical analysis plan, using Stata/SE (version 16). For full details
of study design and conduct see the protocol at <ext-link ext-link-type="uri" xlink:href="https://nejm.org">nejm.org</ext-link>.</p>
              </sec>
            </sec>
            <sec id="S12">
              <title>Results</title>
              <sec id="S13">
                <title>Trial participants</title>
                <p id="P19">From 21 February 2018 to 27 September 2018, 29,949 children underwent screening
and 28,212 were randomly assigned to receive Vi-TCV or MenA vaccine (<xref rid="F1" ref-type="fig">Figure 1</xref>). 28,130 children were vaccinated and included in the ITT
analysis (14,069 in the Vi-TCV group and 14,061 in the MenA group) and 27,882 were
included in the per-protocol analysis (13,945 in the Vi-TCV group and 13,937 in the MenA
group) (<xref rid="F1" ref-type="fig">Figure 1</xref>). Median age was 6 years (range:
0.8–12), and baseline characteristics were similar for the two study groups (<xref rid="T1" ref-type="table">Table 1</xref>).</p>
              </sec>
              <sec id="S14">
                <title>Vaccine efficacy</title>
                <p id="P20">Between 21 February 2018 and 3 April 2020, 7,776 children presented to a passive
surveillance center and met the primary case definition. Blood cultures were collected
from 7,314 (94%). Seventy-five were positive for <italic>S. typhi</italic>. These included
a 9-year-old with two typhoid fever episodes at 24 weeks and 49 weeks after vaccination;
the second episode was therefore excluded from VE analyses. All 75 isolates (100%) were
MDR, and 4/75 (5.3%) were ciprofloxacin-resistant.</p>
                <p id="P21">In the ITT analysis (<xref rid="T2" ref-type="table">Table 2</xref>),
blood-culture -confirmed first episodes of typhoid fever (n=74) occurred in 12 children in
the Vi-TCV group (incidence=46.9 cases per 100,000 person-years) and 62 children in the
MenA group (incidence=243.2 cases per 100,000 person-years). One participant (MenA group)
died from severe typhoid 7 months post-vaccination. VE for the primary outcome of
blood-culture -confirmed typhoid fever, any time after vaccination, was 80.7% (95% CI:
64.2%−89.6%). The Kaplan-Meier curves show separation in cumulative incidence
between Vi-TCV and MenA groups (p&lt;0.001, <xref rid="F2" ref-type="fig">Figure
2</xref>). The estimated VE was 84.6% (95% CI: 50%−94.4%), 82.9% (95% CI:
58.1%−92.5%), and 78.7% (95% CI: 52.8%−91.7%) at 12, 18, and 24 months after
vaccination, respectively. The absolute risk reduction was 3.6 cases per 1,000 vaccinees,
corresponding to a number needed to vaccinate of 278 to prevent one typhoid case. Three
blood-culture -confirmed typhoid fever episodes occurring in the 14 days after vaccination
were excluded from the per-protocol analysis, yielding an overall per-protocol VE of 83.7%
(95% CI 68.1%−91.6%, <xref rid="T2" ref-type="table">Table 2</xref>).</p>
                <p id="P22">For the ITT population, incidence of blood-culture -confirmed typhoid fever in
the MenA group was similar across age groups (<xref rid="T2" ref-type="table">Table
2</xref>). Vi-TCV protective efficacy was 81.2% (95% CI: 54.8%−92.1%) for males
and 80.3% (95% CI: 52.8%−91.8%) for females; and 77.9% (95% CI: 46.5%−90.9%)
for Ndirande and 82.9% (95% CI: 59.2%−92.8%) for Zingwangwa. VE was similar between
the &lt;5 year and ≥5 year age groups (<xref rid="T2" ref-type="table">Table
2</xref> and <xref rid="SD1" ref-type="supplementary-material">supplementary Figure
1</xref>).</p>
              </sec>
              <sec id="S15">
                <title>Safety</title>
                <p id="P23">Three male participants in the MenA group had directly-observed AEs, all graded
mild, within 30 minutes of vaccination. Two (skin rash and syncope) were deemed related to
vaccination, and one (diarrhea) was deemed unrelated.</p>
                <p id="P24">Within 28 days after vaccination, 14 SAEs occurred among 14 participants (12
females, 2 males); 4 in the Vi-TCV group (3 females) and 10 in the MenA group (9 females)
(<xref rid="T3" ref-type="table">Table 3</xref>). Within 6 months of vaccination, 130
SAEs (52 in the Vi-TCV group and 78 in the MenA group) occurred in 118 participants (47 in
the Vi-TCV group and 71 in the MenA group). Although more SAEs were observed among females
than males in the MenA group (52/78 SAEs occurred in females), no sex difference was
observed in the Vi-TCV group (28/52 SAEs occurred in females). The most common SAEs were
respiratory tract infection, gastroenteritis, and malaria. One SAE (MenA group) was deemed
by the investigator as possibly related to vaccination (fever, seizure, and neutrophilia
one week after vaccination). Among 196 children identified as HIV-infected (89 in Vi-TCV
group, 107 in MenA group), 190 were on antiretroviral therapy. Six deaths occurred within
6 months after vaccination (3 females); all were in the MenA group and deemed by the
investigator as unrelated to vaccination.</p>
              </sec>
            </sec>
            <sec id="S16">
              <title>Discussion</title>
              <p id="P25">In this field trial of Vi-TCV in Africa, a single dose Vi-TCV was efficacious in
preventing typhoid fever among children 9 months to 12 years of age. The endemic typhoid
incidence observed across both school-age and pre-school children in the control group
(243/100,000 person-years) was reduced by 80.7% in the Vi-TCV group and Vi-TCV efficacy
remained consistent across children &lt;5 years or ≥5 years at vaccination, and
throughout the observation period. Encouragingly, our VE (80.7% ITT; 83.7% per-protocol) in
Malawi after 18–24 months is consistent with previously reported Vi-TCV VE of 81.6%
after 12 months of follow-up among Nepalese children aged 9 months through 16 years of
age.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> The safety profile was
reassuring, with no excess SAEs in the Vi-TCV group and no AE or SAE considered related to
Vi-TCV. The 6 deaths within the first 6 months occurred in the MenA group and the one death
from typhoid, 7 months after vaccination, also occurred in the MenA group.</p>
              <p id="P26">Typhoid vaccines have previously been trialed in Africa. Among 23,075 South
African children aged 5 to 16 years, a single dose of unconjugated Vi capsular
polysaccharide vaccine was 55–60% effective over 3 years in a randomized controlled
trial.<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> A systemic review and meta-analysis of randomized controlled trials,
including trials and/or populations in Africa, showed cumulative efficacy at 3 years for the
Ty21a oral and the polysaccharide Vi vaccine were similar at 51% (95% CI 36%, 62%) and 55%
(95% CI 30%, 70%), respectively.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Despite
a 2008 WHO recommendation for programmatic use of existing typhoid vaccines in endemic
countries,<sup><xref rid="R28" ref-type="bibr">28</xref></sup> no African country
integrated these vaccines into routine schedules, largely due to the unsuitability in the
youngest children or the need for repeated doses. Typhoid burden in Malawi, and elsewhere in
Africa, is high among both school and pre-school age children, down to one year of
age.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> While these earlier typhoid
vaccines were shown to be efficacious in school-age children, our study, importantly,
demonstrates single dose Vi-TCV efficacy among African children &lt;5 years of age,
whose typhoid incidence was comparably high to that of school-age children. Vi-TCV efficacy
was consistent throughout the study and ongoing typhoid surveillance of this cohort (until
36–42 months) will further assess the durability of protection and enable further
age-stratified analyses in younger children. Analysis of a sub-study cohort is underway and
will provide data on age-stratified immunogenicity.</p>
              <p id="P27">Routine introduction of Vi-TCV among infants, coupled with catch-up campaigns to
the age of 15 years, offers a strategy for typhoid control.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> WHO recommends vaccine introduction in countries with
high incidence or emerging antimicrobial resistance. In February 2019, Zimbabwe<sup><xref rid="R31" ref-type="bibr">31</xref></sup> deployed Vi-TCV programmatically in Africa as
a local, targeted mass-vaccination campaign among children aged 6 months to 15 years in
response to an antimicrobial-resistant typhoid outbreak. In Africa, routine introduction
paired with catch-up campaigns are planned in Zimbabwe and Liberia.</p>
              <p id="P28">Prevention of mother-to-child HIV transmission and successful national roll-out of
antiretroviral treatment have dramatically reduced the prevalence of HIV among children in
Malawi (1% among 0–4 year-olds and 1.5% among 0–14 year-olds in
2015–16).<sup><xref rid="R32" ref-type="bibr">32</xref></sup> It is nonetheless
reassuring that among 196 HIV-infected children identified and randomized in this study, no
excess of SAEs was observed in the Vi-TCV group, and no SAEs were considered related to
vaccination. In sub-Saharan Africa, HIV infection is, counterintuitively, epidemiologically
associated with a 24-fold (95% CI: 9–100) reduction in diagnosis of blood
culture-confirmed typhoid.<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> The continued surveillance in this trial, along with an
ongoing substudy assessing the immunogenicity of a one or two dose schedule of Vi-TCV among
HIV-exposed children at 9- and 15-month immunization visits, will provide additional
information in this vulnerable population.</p>
              <p id="P29">MDR <italic>S. typhi</italic> remains prevalent in sub-Saharan Africa,<sup><xref rid="R8" ref-type="bibr">8</xref></sup> typified by our finding of 100% resistance to
first-line agents for suspected bloodstream infection. In the context of the rise in
fluoroquinolone-resistance among <italic>S. typhi</italic> across Asia,<sup><xref rid="R8" ref-type="bibr">8</xref></sup> the emergence in Malawi of four <italic>S. typhi</italic>
strains with reduced susceptibility to fluroquinolones, from participants enrolled in this
trial, is particularly concerning. Finally, the threat of independent emergence of
azithromycin-resistant typhoid, as seen in several Asian countries,<sup><xref rid="R35" ref-type="bibr">35</xref></sup> adds urgency and relevance to efforts to introduce this
safe and efficacious Vi-TCV vaccine across the African continent and globally. Disclosure
forms provided by the authors are available with the full text of this article at <ext-link ext-link-type="uri" xlink:href="https://NEJM.org">NEJM.org</ext-link>.</p>
            </sec>
            <sec sec-type="supplementary-material" id="SM1">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="SD1">
                <label>Supplement</label>
                <media xlink:href="NEJMoa2035916_Supplement.pdf" orientation="portrait" id="d31e631" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S17">
              <title>Statements and acknowledgments</title>
              <p id="P30">The Typhoid Vaccine Acceleration Consortium (TyVAC) is a partnership between the
Center for Vaccine Development and Global Health at the University of Maryland School of
Medicine, the Oxford Vaccine Group at the University of Oxford, and PATH, an international
non-profit.</p>
              <p id="P31">Funded by a grant from the Bill &amp; Melinda Gates Foundation (OPP1151153) to
TyVAC. The funder of the study had no role in study design; data collection, analysis, or
interpretation; or writing of the report. TyVAC acknowledges Bharat Biotech International
Limited for supplying the investigational vaccine. The Malawi-Liverpool-Wellcome Programme
is core-funded by a grant from the Wellcome Trust (206545/Z/17/Z). M.A.G. is funded by a
Research Professorship from the UK Department of Health National Institute of Health
Research (NIHR300039). M.B. received support from the US National Institutes of Health
[grant number T32 DK067872].</p>
              <p id="P32">The authors thank the study participants and their parents/guardians; the Malawi
Ministries of Health and Education; the Blantyre District Health Officer; the Management and
Paediatric Department of the Queen Elizabeth Central Hospital; the staff of Ndirande,
Zingwangwa and Gateway Health Centres; and the Director and Departments of the
Malawi-Liverpool-Wellcome Programme. We also acknowledge the valuable contributions made by
the following individuals: Malawi study team; Nedson Chasweka, Lucky Somanje, Chrissy Banda,
Josophine Chilongo, Patricia Phula, Georgina Makuta, Monica Kamwana, Moses Kamzati, and
Victoria Mapemba (Blantyre Malaria Project). University of Maryland team; Leslie Jamka,
Shrimati Datta, Ian Woods, Christina Scheele, Tamar Pair. DSMB members; Dr. Roma Chilengi
(Chair), Prof. Dr. Prakash Ghimire, Prof. AKM Nurul Anwar<sup><xref ref-type="fn" rid="FN22">1</xref></sup>, Prof. Dr. S M Shamsuzzaman, Prof. Jalaluddin Ashraful Haq, Dr. Nur
Haque Alam, Dr. Tisungane Knox Titus Mvalo, and Dr. Mary E Putt.</p>
            </ack>
            <fn-group>
              <fn id="FN22">
                <label>1</label>
                <p id="P33">Passed away prior to publication.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="book"><collab>Global Burden of Disease Collaborative
Network</collab>. <source>GBD 2020 Cause and Risk Summaries: Typhoid fever —
level 4 cause</source>. <publisher-loc>Seattle, United States</publisher-loc>:
<publisher-name>Institute for Health Metrics and Evaluation (IHME)</publisher-name>.
<year>2020</year>; <comment>Available from</comment>: <comment><ext-link ext-link-type="uri" xlink:href="http://www.healthdata.org/results/gbd_summaries/2019/typhoid-fever-level-4-cause">http://www.healthdata.org/results/gbd_summaries/2019/typhoid-fever-level-4-cause</ext-link></comment></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><name><surname>Antillón</surname><given-names>M</given-names></name>, <name><surname>Warren</surname><given-names>JL</given-names></name>, <name><surname>Crawford</surname><given-names>FW</given-names></name>, <etal/><article-title>The burden of typhoid fever in low- and middle-income countries: a
meta-regression approach</article-title>. <source>PLoS Negl Trop Dis</source><year>2017</year>;<volume>11</volume>(<issue>2</issue>):<fpage>1</fpage>–<lpage>21</lpage>.</mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><name><surname>Marks</surname><given-names>F</given-names></name>, <name><surname>von Kalckreuth</surname><given-names>V</given-names></name>, <name><surname>Aaby</surname><given-names>P</given-names></name>, <etal/><article-title>Incidence of invasive salmonella disease in sub-Saharan Africa: a
multicentre population-based surveillance study</article-title>. <source>Lancet Global
Health</source><year>2017</year>;<volume>5</volume>(<issue>3</issue>):<fpage>e310</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">28193398</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><name><surname>Breiman</surname><given-names>RF</given-names></name>, <name><surname>Cosmas</surname><given-names>L</given-names></name>, <name><surname>Njuguna</surname><given-names>H</given-names></name>, <etal/><article-title>Population-based incidence of typhoid fever in an urban informal settlement
and a rural area in Kenya: implications for typhoid vaccine use in
Africa</article-title>. <source>PLoS One</source><year>2012</year>;<volume>7</volume>(<issue>1</issue>):<fpage>e29119</fpage>.<pub-id pub-id-type="pmid">22276105</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><name><surname>Meiring</surname><given-names>JE</given-names></name>, <name><surname>Patel</surname><given-names>P</given-names></name>, <name><surname>Patel</surname><given-names>P</given-names></name>, <name><surname>Gordon</surname><given-names>MA</given-names></name>. <article-title>Typhoid conjugate vaccines: making
vaccine history in Africa</article-title>. <source>Expert Review of Vaccines</source><year>2018</year>;<volume>17</volume>(<issue>8</issue>):<fpage>673</fpage>–<lpage>676</lpage>.<pub-id pub-id-type="pmid">29972655</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>VK</given-names></name>, <name><surname>Holt</surname><given-names>KE</given-names></name>, <name><surname>Okoro</surname><given-names>C</given-names></name>, <etal/><article-title>Molecular surveillance identifies multiple transmissions of typhoid in West
Africa</article-title>. <source>PLoS Negl Trop Dis</source><year>2016</year>;<volume>10</volume>(<issue>9</issue>):<fpage>1</fpage>–<lpage>22</lpage>.</mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>VK</given-names></name>, <name><surname>Baker</surname><given-names>S</given-names></name>, <name><surname>Pickard</surname><given-names>DJ</given-names></name>, <etal/><article-title>Phylogeographical analysis of the dominant multidrug-resistant H58 clade of
<italic>Salmonella</italic> Typhi identifies inter- and intracontinental transmission
events</article-title>. <source>Nat Genet</source><year>2015</year>;<volume>47</volume>(<issue>6</issue>):<fpage>632</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">25961941</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><name><surname>Britto</surname><given-names>CD</given-names></name>, <name><surname>Wong</surname><given-names>VK</given-names></name>, <name><surname>Dougan</surname><given-names>G</given-names></name>, <name><surname>Pollard</surname><given-names>AJ</given-names></name>. <article-title>A systematic review of
antimicrobial resistance in <italic>Salmonella enterica</italic> serovar Typhi, the
etiological agent of typhoid</article-title>. <source>PLoS Negl Trop Dis</source><year>2018</year>;<volume>12</volume>(<issue>10</issue>):<fpage>1</fpage>–<lpage>15</lpage>.</mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><name><surname>Feasey</surname><given-names>NA</given-names></name>, <name><surname>Gaskell</surname><given-names>K</given-names></name>, <name><surname>Wong</surname><given-names>V</given-names></name>, <etal/><article-title>Rapid emergence of multidrug resistant, H58-lineage
<italic>Salmonella</italic> Typhi in Blantyre, Malawi</article-title>. <source>PLoS
Negl Trop Dis</source><year>2015</year>;<volume>9</volume>(<issue>4</issue>):<fpage>1</fpage>–<lpage>13</lpage>.</mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><name><surname>Olgemoeller</surname><given-names>F</given-names></name>, <name><surname>Waluza</surname><given-names>JJ</given-names></name>, <name><surname>Zeka</surname><given-names>D</given-names></name>, <etal/><article-title>Intestinal perforations associated with a high mortality and frequent
complications during an epidemic of multidrug-resistant typhoid fever in Blantyre,
Malawi</article-title>. <source>Clin Infect Dis</source><year>2020</year>;<volume>71</volume>(<issue>Suppl
2</issue>):<fpage>S96</fpage>–<lpage>101</lpage>.<pub-id pub-id-type="pmid">32725231</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><name><surname>Feasey</surname><given-names>NA</given-names></name>, <name><surname>Masesa</surname><given-names>C</given-names></name>, <name><surname>Jassi</surname><given-names>C</given-names></name>, <etal/><article-title>Three epidemics of invasive multidrug-resistant <italic>Salmonella</italic>
bloodstream infection in Blantyre, Malawi, 1998–2014</article-title>.
<source>Clin Infect Dis</source><year>2015</year>;<volume>61</volume>(<issue>suppl
4</issue>):<fpage>S363</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">26449953</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><name><surname>Musicha</surname><given-names>P</given-names></name>, <name><surname>Cornick</surname><given-names>JE</given-names></name>, <name><surname>Bar-Zeev</surname><given-names>N</given-names></name>, <etal/><article-title>Trends in antimicrobial resistance in bloodstream infection isolates at a
large urban hospital in Malawi (1998–2016): a surveillance study</article-title>.
<source>Lancet Infect Dis</source><year>2017</year>;<volume>17</volume>(<issue>10</issue>):<fpage>1042</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">28818544</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><name><surname>Mutai</surname><given-names>WC</given-names></name>, <name><surname>Muigai</surname><given-names>AWT</given-names></name>, <name><surname>Waiyaki</surname><given-names>P</given-names></name>, <name><surname>Kariuki</surname><given-names>S</given-names></name>. <article-title>Multi-drug resistant
<italic>Salmonella enterica</italic> serovar Typhi isolates with reduced
susceptibility to ciprofloxacin in Kenya</article-title>. <source>BMC Microbiol</source><year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>4</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">29433447</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><name><surname>Tack</surname><given-names>B</given-names></name>, <name><surname>Phoba</surname><given-names>MF</given-names></name>, <name><surname>Van Puyvelde</surname><given-names>S</given-names></name>, <etal/><article-title><italic>Salmonella</italic> Typhi from blood cultures in the Democratic
Republic of the Congo: a 10-year surveillance</article-title>. <source>Clin Infect
Dis</source><year>2019</year>;<volume>68</volume>(<issue>Suppl
2</issue>):<fpage>S130</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">30845337</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><name><surname>Klemm</surname><given-names>EJ</given-names></name>, <name><surname>Shakoor</surname><given-names>S</given-names></name>, <name><surname>Page</surname><given-names>AJ</given-names></name>, <etal/><article-title>Emergence of an extensively drug-resistant <italic>Salmonella
enterica</italic> serovar Typhi clone harboring a promiscuous plasmid encoding
resistance to fluoroquinolones and third-generation cephalosporins</article-title>.
<source>MBio</source><year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>e00105</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">29463654</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><name><surname>Burki</surname><given-names>T.</given-names></name><article-title>Typhoid conjugate vaccine gets WHO prequalification</article-title>.
<source>Lancet Infect Dis</source><year>2018</year>;<volume>18</volume>(<issue>3</issue>):<fpage>258</fpage>.<pub-id pub-id-type="pmid">29485093</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><name><surname>Shakya</surname><given-names>M</given-names></name>, <name><surname>Colin-Jones</surname><given-names>R</given-names></name>, <name><surname>Theiss-Nyland</surname><given-names>K</given-names></name>, <etal/><article-title>Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in
Nepal</article-title>. <source>N Engl J Med</source><year>2019</year>;<volume>381</volume>(<issue>23</issue>):<fpage>2209</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">31800986</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="book"><name><surname>Meiring</surname><given-names>JE</given-names></name>, <name><surname>Gibani</surname><given-names>M</given-names></name>, <name><surname>Basnyat</surname><given-names>B</given-names></name>, <etal/><part-title>The Typhoid Vaccine Acceleration Consortium (TyVAC): vaccine effectiveness
study designs: accelerating the introduction of typhoid conjugate vaccines and reducing
the global burden of enteric fever</part-title>. <source>Report from a meeting held
on 26–27 October 2016</source>, <publisher-loc>Oxford</publisher-loc>.
<publisher-name>Vaccine</publisher-name><year>2017</year>;<volume>35</volume>(<issue>38</issue>):<fpage>5081</fpage>–<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><name><surname>Theiss-Nyland</surname><given-names>K</given-names></name>, <name><surname>Shakya</surname><given-names>M</given-names></name>, <name><surname>Colin-Jones</surname><given-names>R</given-names></name>, <etal/><article-title>Assessing the impact of a VI-polysaccharide conjugate vaccine in preventing
typhoid infections among nepalese children: a protocol for a phase III, randomized
control trial</article-title>. <source>Clin Infect Dis</source><year>2019</year>;<volume>68</volume>(<issue>Suppl
2</issue>):<fpage>S67</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">30845329</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><name><surname>N’cho</surname><given-names>HS</given-names></name>, <name><surname>Masunda</surname><given-names>KPE</given-names></name>, <name><surname>Mukeredzi</surname><given-names>I</given-names></name>, <etal/><article-title><italic>Notes from the Field:</italic> Typhoid Fever Outbreak —
Harare, Zimbabwe, October 2017–February 2018</article-title>. <source>MMWR Morb
Mortal Wkly Rep</source><year>2019</year>;<volume>68</volume>(<issue>2</issue>):<fpage>44</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">30653487</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><name><surname>Kabwama</surname><given-names>SN</given-names></name>, <name><surname>Bulage</surname><given-names>L</given-names></name>, <name><surname>Nsubuga</surname><given-names>F</given-names></name>, <etal/><article-title>A large and persistent outbreak of typhoid fever caused by consuming
contaminated water and street-vended beverages: Kampala, Uganda, January - June
2015</article-title>. <source>BMC Public Health</source><year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>9</lpage>.
<comment>Available from</comment>: <pub-id pub-id-type="doi">10.1186/s12889-016-4002-0</pub-id><pub-id pub-id-type="pmid">28049454</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><name><surname>Meiring</surname><given-names>JE</given-names></name>, <name><surname>Laurens</surname><given-names>MB</given-names></name>, <name><surname>Patel</surname><given-names>P</given-names></name>, <etal/><article-title>Typhoid vaccine acceleration consortium Malawi: A Phase III, randomized,
double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine
among children in Blantyre, Malawi</article-title>. <source>Clin Infect Dis</source><year>2019</year>;<volume>68</volume>(<issue>Suppl
2</issue>):<fpage>S50</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">30845320</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><name><surname>Meiring</surname><given-names>JE</given-names></name>, <name><surname>Sambakunsi</surname><given-names>R</given-names></name>, <name><surname>Moyo</surname><given-names>E</given-names></name>, <etal/><article-title>Community engagement before initiation of typhoid conjugate vaccine trial
in schools in two urban townships in Blantyre, Malawi: Experience and
lessons</article-title>. <source>Clin Infect Dis</source><year>2019</year>;<volume>68</volume>(<issue>Suppl
2</issue>):<fpage>S146</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">30845322</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><collab>The European Committee on Antimicrobial
Susceptibility Testing</collab>. <source>Breakpoint tables for interpretation of MICs
and zone diameters, version 10.0</source>. <year>2020</year> [<comment>cited</comment>
<date-in-citation>2020 Dec
9</date-in-citation>];<fpage>1</fpage>–<lpage>128</lpage>. <comment>Available
from</comment>: <comment><ext-link ext-link-type="uri" xlink:href="https://eucast.org/">https://eucast.org/</ext-link></comment></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><name><surname>Klugman</surname><given-names>KP</given-names></name>, <name><surname>Koornhof</surname><given-names>HJ</given-names></name>, <name><surname>Schneerson</surname><given-names>R</given-names></name>, <etal/><article-title>Protective activity of Vi capsular polysaccharide vaccine against typhoid
fever</article-title>. <source>Lancet</source><year>1987</year>;<volume>330</volume>(<issue>8569</issue>):<fpage>1165</fpage>–<lpage>9</lpage>.</mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><name><surname>Klugman</surname><given-names>KP</given-names></name>, <name><surname>Koornhof</surname><given-names>HJ</given-names></name>, <name><surname>Robbins</surname><given-names>JB</given-names></name>, <name><surname>Le Cam</surname><given-names>NN</given-names></name>. <article-title>Immunogenicity, efficacy and
serological correlate of protection of Salmonella typhi Vi capsular polysaccharide
vaccine three years after immunization</article-title>. <source>Vaccine</source><year>1996</year>;<volume>14</volume>(<issue>5</issue>):<fpage>435</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">8735556</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><name><surname>Fraser</surname><given-names>A</given-names></name>, <name><surname>Paul</surname><given-names>M</given-names></name>, <name><surname>Goldberg</surname><given-names>E</given-names></name>, <name><surname>Acosta</surname><given-names>CJ</given-names></name>, <name><surname>Leibovici</surname><given-names>L</given-names></name>. <article-title>Typhoid fever vaccines: systematic
review and meta-analysis of randomised controlled trials</article-title>.
<source>Vaccine</source><year>2007</year>;<volume>25</volume>(<issue>45</issue>):<fpage>7848</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">17928109</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><collab>WHO</collab>. <article-title>Typhoid
vaccines: WHO position paper</article-title>. <source>Wkly Epidemiol Rec</source><year>2008</year>;<volume>83</volume>(<issue>6</issue>):<fpage>49</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">18260212</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><name><surname>Feasey</surname><given-names>NA</given-names></name>, <name><surname>Masesa</surname><given-names>C</given-names></name>, <name><surname>Jassi</surname><given-names>C</given-names></name>, <etal/><article-title>Three epidemics of invasive multidrug-resistant salmonella bloodstream
infection in Blantyre, Malawi, 1998–2014</article-title>. <source>Clin Infect
Dis</source><year>2015</year>;<volume>61</volume>(<issue>Suppl
4</issue>):<fpage>S363</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">26449953</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><name><surname>Bilcke</surname><given-names>J</given-names></name>, <name><surname>Antillón</surname><given-names>M</given-names></name>, <name><surname>Pieters</surname><given-names>Z</given-names></name>, <etal/><article-title>Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate
vaccine in Gavi-eligible countries: a modelling study</article-title>. <source>Lancet
Infect Dis</source><year>2019</year>;<volume>19</volume>(<issue>7</issue>):<fpage>728</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">31130329</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><name><surname>Olaru</surname><given-names>ID</given-names></name>, <name><surname>Mtapuri-Zinyowera</surname><given-names>S</given-names></name>, <name><surname>Feasey</surname><given-names>N</given-names></name>, <name><surname>Ferrand</surname><given-names>RA</given-names></name>, <name><surname>Kranzer</surname><given-names>K</given-names></name>. <article-title>Typhoid Vi-conjugate vaccine for
outbreak control in Zimbabwe</article-title>. <source>Lancet Infect Dis</source><year>2019</year>;<volume>19</volume>(<issue>9</issue>):<fpage>930</fpage>.
<comment>Available from</comment>: <pub-id pub-id-type="doi">10.1016/S1473-3099(19)30425-6</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><source>Malawi Population-based HIV Impact
Assessment (PHIA)</source>. <comment>Available from</comment>: <comment><ext-link ext-link-type="uri" xlink:href="https://phia.icap.columbia.edu/">https://phia.icap.columbia.edu/</ext-link></comment></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>JH</given-names></name>, <name><surname>Im</surname><given-names>J</given-names></name>, <name><surname>Parajulee</surname><given-names>P</given-names></name>, <etal/><article-title>A systematic review of typhoid fever occurrence in Africa</article-title>.
<source>Clin Infect Dis</source><year>2019</year>;<volume>69</volume>(<issue>Suppl
6</issue>):<fpage>S492</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">31665777</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><name><surname>Levine</surname><given-names>MM</given-names></name>, <name><surname>Farag</surname><given-names>TH</given-names></name>. <article-title>Invasive salmonella infections and
HIV in northern Tanzania</article-title>. <source>Clin Infect Dis</source><year>2011</year>;<volume>52</volume>(<issue>3</issue>):<fpage>349</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">21217182</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><name><surname>Carey</surname><given-names>ME</given-names></name>, <name><surname>Jain</surname><given-names>R</given-names></name>, <name><surname>Yousuf</surname><given-names>M</given-names></name>, <name><surname>Maes</surname><given-names>M</given-names></name>, <name><surname>Dyson</surname><given-names>ZA</given-names></name>. <article-title>Spontaneous emergence of
azithromycin resistance in independent lineages of <italic>Salmonella</italic> Typhi in
Northern India</article-title>. <source>Clin Infect Dis</source>. <comment>In
Press</comment>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig id="F1" orientation="portrait" position="float">
              <label>Figure 1:</label>
              <caption>
                <title>Disposition of participants (CONSORT flow diagram)</title>
                <p id="P34">*MenA group A meningococcal</p>
                <p id="P344">†Randomization deviation: Two participants received the same PID. The
second participant who received a duplicate PID was assigned a new PID after randomization
and excluded from per-protocol analysis.</p>
              </caption>
              <graphic xlink:href="nihms-1711373-f0001"/>
            </fig>
            <fig id="F2" orientation="portrait" position="float">
              <label>Figure 2.</label>
              <caption>
                <p id="P35">Kaplan-Meier Estimates of the Cumulative Incidence of Blood Culture-Positive
Typhoid Fever, By Vaccine Group, Intention to Treat Population.</p>
              </caption>
              <graphic xlink:href="nihms-1711373-f0002"/>
            </fig>
            <table-wrap id="T1" orientation="portrait" position="float">
              <label>Table 1.</label>
              <caption>
                <p id="P36">Baseline Characteristics of Children Enrolled in Efficacy Study of Typhoid
Conjugate Vaccine (TCV), Intention to Treat Population.</p>
              </caption>
              <table frame="box" rules="all">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Variable</th>
                    <th align="center" valign="middle" rowspan="1" colspan="1">TCV (N=14,069)</th>
                    <th align="center" valign="middle" rowspan="1" colspan="1">MenA<xref rid="TFN1" ref-type="table-fn">*</xref>
Vaccine (N=14,061)</th>
                    <th align="center" valign="middle" rowspan="1" colspan="1">Total (N=28,130)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Age at enrollment - years</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> Mean (±SD)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">6.1 ±3.3</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">6.2 ±3.3</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">6.1 ±3.3</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> Median (range)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">6 (0.8–12)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">6 (0.8–12)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">6 (0.8–12)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Age group—no. (%)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> &lt; 2years</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">1552 (11)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">1598 (11.4)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">3150 (11.2)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> ≥2 and &lt;5years</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">3506 (24.9)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">3581 (25.5)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">7087 (25.2)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> ≥ 5years</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">9011 (64.1)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">8882 (63.2)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">17,893 (63.6)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Sex— no. (%)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> Female</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">7065 (50.2)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">7231 (51.4)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">14,296 (50.8)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> Male</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">7004 (49.8)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">6830 (48.6)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">13,834 (49.2)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1">Study site— no. (%)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                    <td align="center" valign="middle" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> Ndirande</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">8863 (63)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">8832 (62.8)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">17,695 (62.9)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"> Zingwangwa</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">5206 (37)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">5229 (37.2)</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">10,435 (37.1)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN1">
                  <label>*</label>
                  <p id="P37">MenA - group A meningococcal.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="T2" orientation="landscape" position="float">
              <label>Table 2.</label>
              <caption>
                <p id="P38">Occurrence of Blood Culture-Confirmed Typhoid Fever and Efficacy of Typhoid
Conjugate Vaccine (TCV).</p>
              </caption>
              <table frame="box" rules="all">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th rowspan="3" align="left" valign="top" colspan="1">Variable</th>
                    <th colspan="3" align="center" valign="top" rowspan="1">TCV</th>
                    <th colspan="3" align="center" valign="top" rowspan="1">MenA Vaccine</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Efficacy of TCV</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Absolute Risk Reduction</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Number Needed to Vaccinate<xref rid="TFN6" ref-type="table-fn">††</xref></th>
                  </tr>
                  <tr>
                    <th align="center" valign="top" rowspan="1" colspan="1">Participants (total follow-up time)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Cases</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Incidence</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Participants (total follow-up time)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Cases</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Incidence</th>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <th colspan="2" align="center" valign="middle" rowspan="1">no. (person-years)</th>
                    <th align="center" valign="middle" rowspan="1" colspan="1">no. of cases/100,000 person-years (95% CI)</th>
                    <th colspan="2" align="center" valign="middle" rowspan="1">no. (person-years)</th>
                    <th align="center" valign="middle" rowspan="1" colspan="1">no. of cases/100,000 person-years (95% CI)</th>
                    <th align="center" valign="middle" rowspan="1" colspan="1">percent (95% CI)</th>
                    <th align="center" valign="middle" rowspan="1" colspan="1">per 1000 (95% CI)</th>
                    <th align="center" valign="middle" rowspan="1" colspan="1">no. (95% CI)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td colspan="10" align="left" valign="top" rowspan="1">Intention-to-treat population (from time of
vaccination)</td>
                  </tr>
                  <tr>
                    <td colspan="10" align="left" valign="top" rowspan="1">Age Group</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Total participants</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14,069 (25,577)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">12</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">46.9 (24.2–82)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14,061 (25,493)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">62</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">243.2 (186.5–311.8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">80.7 <xref rid="TFN3" ref-type="table-fn">†</xref> (64.2–89.6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3.6 <xref rid="TFN4" ref-type="table-fn">§</xref>
(2.4–4.8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">277.8 (208.3–416.7)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> &lt;5years</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5058 (9086)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">55 (17.9–128.4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5179 (9305)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">20</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">215 (131.3–332)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">74.4 (31.7–90.4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.9 (1–4.8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">344.8 (208.3–1000)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> ≥5years</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">9011 (16,491)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">7</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">42.5 (17.1–87.5)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">8882 (16,188)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">42</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">259.5 (187–350.7)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">83.7 (63.6–92.7)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4 (2.4–5.5)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">250 (181.8–416.7)</td>
                  </tr>
                  <tr>
                    <td colspan="10" align="left" valign="top" rowspan="1">Per-protocol population (14 days after
vaccination)</td>
                  </tr>
                  <tr>
                    <td colspan="10" align="left" valign="top" rowspan="1">Age Group</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Total participants</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13,945 (25,323)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">39.5 (18.9–72.6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13,937 (25,239)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">61</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">241.7 (184.9–310.5)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">83.7 <xref rid="TFN3" ref-type="table-fn">†</xref> (68.1–91.6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3.7 <xref rid="TFN4" ref-type="table-fn">§</xref>
(2.5–4.8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">270.3 (208.3–400)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> &lt;5years</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5044 (9057)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">55.2 (17.9–128.8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5158 (9261)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">20</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">216 (131.9–333.5)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">74.4 (31.8–90.4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.9 (1.0–4.8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">344.8 (208.3–1000)</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> ≥5years</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">8901 (16,267)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">30.7 (10–71.7)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">8779 (15,978)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">41</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">256.6 (184.1–348.1)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">88 (69.7–95.3)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4.1 (2.6–5.6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">243.9 (178.6–384.6)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN2">
                  <label>*</label>
                  <p id="P39">CI denotes confidence interval, and MenA group A meningococcal.</p>
                </fn>
                <fn id="TFN3">
                  <label>†</label>
                  <p id="P40">p-value &lt;0.001</p>
                </fn>
                <fn id="TFN4">
                  <label>§</label>
                  <p id="P41">p-value &lt;0.001</p>
                </fn>
                <fn id="TFN5">
                  <p id="P42">Absolute risk reduction (=risk in MenA – risk in TCV) is the total
reduction in risk of blood culture-confirmed typhoid fever that results from TCV
vaccination.</p>
                </fn>
                <fn id="TFN6">
                  <label>††</label>
                  <p id="P43">The number of children needed to be vaccinated to prevent one case of
blood-culture confirmed typhoid fever.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="T3" orientation="portrait" position="float">
              <label>Table 3.</label>
              <caption>
                <p id="P44">Safety Outcomes by Vaccine Group, Intention to Treat Population.</p>
              </caption>
              <table frame="box" rules="all">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Variable</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">TCV</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">MenA<xref rid="TFN7" ref-type="table-fn">*</xref>
Vaccine</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Total</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td colspan="3" align="center" valign="top" rowspan="1">
                      <bold>no. of participants</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Total participants</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14,069</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14,061</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">28,130</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Participants with serious adverse events within 28 days
after vaccination</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Participants with serious adverse events within 6 months
after vaccination</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">47</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">71</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">118</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td colspan="3" align="center" valign="top" rowspan="1">
                      <bold>no. of events observed</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Serious adverse events within 28 days after vaccination</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Infections and infestations</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">8</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">11</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Other</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Serious adverse events within 6 months after vaccination</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">52</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">78</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">130</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Infections and infestations</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">34</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">55</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">89</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">  Respiratory tract infection</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">16</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">21</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">37</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">  Gastroenteritis</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">11</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">8</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">19</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">  Malaria</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">  Other infections</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">16</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">19</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Nervous system disorders<xref rid="TFN9" ref-type="table-fn">†</xref></td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">9</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">15</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Injury, poisoning and procedural
complications<xref rid="TFN10" ref-type="table-fn">§</xref></td>
                    <td align="center" valign="top" rowspan="1" colspan="1">7</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"> Other</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">8</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Deaths within 6 months after vaccination</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6 <xref rid="TFN11" ref-type="table-fn">ǂ</xref></td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN7">
                  <label>*</label>
                  <p id="P45">MenA group A meningococcal vaccine.</p>
                </fn>
                <fn id="TFN8">
                  <p id="P46">For the serious adverse events reported in this table, the assigned vaccine
group is the same as the received vaccine group.</p>
                </fn>
                <fn id="TFN9">
                  <label>†</label>
                  <p id="P47">Includes febrile convulsion and seizure.</p>
                </fn>
                <fn id="TFN10">
                  <label>§</label>
                  <p id="P48">Includes fractures and road traffic accidents.</p>
                </fn>
                <fn id="TFN11">
                  <label>ǂ</label>
                  <p id="P49">6 causes of death: Acute kidney injury secondary to hypovolemia;
intra-abdominal infection secondary to shunt infection; death in the community with
unknown cause; tracheoesophageal fistula after foreign body ingestion; massive trauma;
chronic malnutrition complicated by possible TB, blood-culture negative sepsis or
malignancy.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
